Drugs / ZORECIMERAN
ZORECIMERAN
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04449276 | Jun 2020 → Dec 2021 | COVID-19, severe acute respiratory syndrome | CureVac | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04515147 | Sep 2020 → Feb 2022 | COVID-19, severe acute respiratory syndrome | CureVac | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04652102 | Dec 2020 → Jun 2022 | COVID-19 | CureVac | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT04848467 | Oct → Nov 2021 | COVID-19 | Bayer | Withdrawn | No outcome recorded |
| Phase 3 | NCT04838847 | Oct 2021 → Jan 2022 | COVID-19, severe acute respiratory syndrome | CureVac | Withdrawn | No outcome recorded |
| Phase 3 | NCT04860258 | Apr → Sep 2021 | COVID-19, severe acute respiratory syndrome | CureVac | Terminated | No outcome recorded |
| Phase 3 | NCT04674189 | Dec 2020 → Jun 2022 | COVID-19, severe acute respiratory syndrome | CureVac | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZORECIMERAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802204 ↗ |
| Known as | CV-07050101 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802204 ↗ |
| Known as | CVnCoV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04449276 ↗ |
| Modality | Messenger RNA (mRNA) | “Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly” NCT04449276 ↗ |
| Route | Intramuscular | “Participants will receive an intramuscular injection by needle in the deltoid area.” NCT04449276 ↗ |